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Targeted Tumor Detection: Guidelines for Developing Biotinylated 
Diagnostics  
Joo Hee Jang,a,‡ Woo Ri Kim,b,‡ Amit Sharma,a,‡ Suk Hee Cho,b Tony D. James,c,* Chulhun Kang,b,* 
and Jong Seung Kima,*  
The challenge in achieving precision medicine relies on how to 
advance and/or enhance new as well as old therapeutic strategies. 
Here, we highlight the significant role hydrophilicity of biotinylated 
fluorescent probe’s plays on their cellular uptake behaviour.  
Cancer is a near-term objective of the precision medicine initiative 
(2015) which aims to revolutionize current health programs by 
tailoring therapeutics towards individual patients.1 The overarching 
goal behind this initiative is for medicinal care providers to decrease 
the cancer modalities and morbidities, regardless of the cancer 
subtype, contingent on the results obtained from reliable assays for 
relevant markers from patients, that are pertinent for disease 
prevention.2 However, this monumental task presents numerous 
biological challenges such as pathological and physiological 
complications, non-targeted delivery due to genetic heterogeneity 
within tumors, dynamic drug resistance, problems with cancer 
subtype classification and associated off-target side effects. With the 
revolution in cancer genomics, immense effort has been directed 
towards the development of non-invasive biomarkers for assessing 
and transferring genetic information into clinical practices in order to 
facilitate diagnosis, monitor the therapeutic response and patient 
stratifications.3 Generally, development programs are endorsed 
under regulatory guidelines for better outcomes from various clinical 
processes and implementations.4 However, regardless of these huge 
endeavors and resources provided, the real hurdles confronting the 
clinical development and endorsement of current precision based 
regimens are selectivity, tissue penetration with adequate uptake 
followed by pathways for drug clearing. In order to take full 
advantage of advanced cancer genomics, we require a better 
understanding of the mechanisms responsible for better targeted 
diagnostics leading to improved therapeutics.  
Biotin (vitamin H), a critical cofactor for carboxylase activity, is 
involved in fatty acid synthesis, branched amino acids catabolism and 
gluconeogenesis5,6 and is preferentially delivered into rapidly 
proliferating cells including cancer cells (ovarian, colorectral, etc.), 
through the overexpressed sodium dependent multivitamin 
transporter (SMVT) on the cell surface, whose activity is additionally 
regulated by protein kinase C (PKC).6,7 Biotin-conjugation is one of 
the most plausible choices in developing various cancer selective 
prodrugs, polymeric carriers for drug delivery, and theranostic 
systems.8,9 Recently, biotin has been extensively used as a protein 
labeling tool in order to identify various protein interactions.10 In 
theranostic biotin-conjugates, a biotin unit is linked through a self-
immolative linker to the drug molecule, which may vary from 
lipophilic drug11 to highly polar peptide.12 In general, cellular uptake 
of hydrophilic molecules may be aided by the corresponding 
membrane proteins, whereas the hydrophobic molecules, for 
instance, steroid hormones, simply diffuse through the membrane.13  
In this context, despite the incorporation of a biotin moiety for 
SMVT targeting, one may ask whether or not the hydrophobicity of 
biotin-conjugates plays an adverse role in their cellular uptake. 
Moreover, the biological pathway responsible for theranostic biotin-
conjugate’s uptake still remains elusive. These factors are critical for 
the development of smarter biotin-conjugates in order to widen the 
tenets of precision medicine with an emphasis on disease prevention. 
In order to investigate the role of hydrophilicity in biotinylated 
conjugate towards cellular uptake, we designed biotin-conjugated 
fluorescent probes (4-6) (Scheme 1), possessing dodecyl, hexyl, 
diethylene glycol to adjust their overall hydrophobicity and the 
corresponding non-biotin analogs (1-3) were used as controls 
(Scheme 1). The 4-amino-1,8-naphthalimide fluorophore was chosen 
due to its strong emission. Additionally, the two photon properties 
can afford better cell imaging efficiency with minimal background 
and enhanced light penetration. The in vitro cellular uptake behavior 
and mechanism were investigated against HeLa cells. Compared to 
other conjugates, biotin fluorescent probe 5 with log Poct ~1 exhibited 
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preferential cell membrane uptake via SMVT proteins under PKC-
mediation using intracellular ATPs. 
Compounds 1-6 were synthesized according to scheme S1 (ESI †) 
in good yield. Spectroscopic studies of the probes were undertaken 
using UV/Vis absorption and fluorescence spectroscopy. These 
probes exhibit a broad absorption band at 430 (in toluene), 433 (in 
acetonitrile), and 440 nm (in PBS) respectively, (Fig. S1) with a 
bandwidth of ~ 75 nm. The corresponding fluorescence emission 
bands of the probes in toluene and acetonitrile were slightly blue-
shifted with enhanced intensities (505 and 524 nm respectively) 
when compared to the PBS (545 nm) system. Since the internal 
charge-transfer (ICT) excited state phenomenon in these probes 
offers a substantial excited-state dipole moment, which can be 
stabilized/destabilized depending upon the choice of solvent. The 
lower fluorescent emission intensity of the probes in PBS is ascribed 
to their hydrogen bond donor (HBD) or hydrogen bond acceptor 
(HBA) ability.14 
 
Scheme 1 Chemical structure of the non-biotin (1-3) and biotin-conjugated probes (4-6).  
To examine the cell uptake behavior of biotin-conjugates, we 
performed fluorescent confocal microscopic experiments in HeLa 
cells for each conjugate (1-6). As shown in Fig. S2(a), probe 1 with a 
dodecyl group displayed the strongest fluorescence intensity among 
the non-biotin probes (1-3) and its intensity is expected to keep on 
increasing even after 60 min. Due to the more hydrophobic tail of 
this molecule, it penetrates into the cell membrane via diffusion. 
Conversely, among the biotin-conjugates (4-6), the largest intensity 
was observed for the system with a hexyl moiety (5), while one with 
a more hydrophobic dodecyl (4) and a hydrophilic hydroxylethyl-
oxyethyl moiety (6) do not display comparable fluorescence intensity 
(Fig S2b). These results indicate that the biotin-conjugates enter the 
cells through an alternate pathway from that of the non-biotin 
counterparts. 
In order to investigate the detailed cellular uptake mechanism of 
the biotin-conjugates (4-6), a time course analysis of the 
fluorescence intensity in the cells was carried out for probes 2 and 5 
at various concentrations. We have found that the enhancement of 
fluorescence displays both time and concentration dependent 
behavior (Fig. 1). And, probe 5 shows 6 times higher fluorescence 
intensity than 2 incorporating the same alkyl chain, indicating that 
the biotin moiety plays a significant role in the cellular uptake. 
However, what makes the dramatic difference of uptake behavior 
among the biotin-conjugates shown in Fig S2b. The most apparent 
difference among the conjugate structures was the probes’ 
hydrophilicity. Thereby, we measured the partition-coefficients 
(logPoct) of the probes according to the solubility in n-octanol and 
MOPS buffer (Table S1 and Fig. 2). The logPoct values for 4-6 are 1.29, 
1.03, and 0.807, respectively. These results suggest an optimum 
hydrophobicity for the biotin-conjugates with a logPoct value of about 
1.0  
 
Fig. 1 Confocal microscopy images of HeLa cells upon treatment with probes 2 and 5. (a) 
The fluorescent images were obtained at variable time (2 μM each); (b) and at variable 
probe’s concentration for 10 min. The cells were incubated in high glucose serum free 
DMEM media at 37 ℃, λex = 458 nm, bandpath filter (505-550 nm). (c , d) Fluorescence 
intensities (a.u.) per cell in the images of the panel (a) and (b) respectively. The images 
were obtained using Image J software. The data are presented as mean ± SD (n=5).                  
 
Subsequently, in order to identify the intracellular location of 2 and 
5, a series of colocalization experiments were performed using 
commercially available organelle selective markers. As seen in Fig. S3, 
the green-channel fluorescence intensity of 5 showed an excellent 
overlay with the red-channel fluorescence of ER (Pearson’s 
correlation coefficient (PCC) is 0.9729), whereas the overlap with 
other trackers were relatively poor (Lyso; 0.4617 and Mito; 0.5576). 
Its preference for the ER could be explained by the fact that the ER is 
the metabolic center of various lipophilic compounds such as 
xenobitics and lipids with the largest membrane area among the 
organelles. In contrast, the non-biotin-conjugate, 2 was localized in 
the ER as well as mitochondria (PCC = 0.9373 and 0.7809, 
respectively). 
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Fig. 2 Lipophilicity of probes (1-6) according to logPoct value.  
It is well known that biotin’s uptake is regulated through SMVT, 
and it would be natural to ask whether biotin-conjugates enter the 
cells via the same mechanism. To the best of our knowledge, this has 
never been reported before. The uptake of probe 5 in Fig. 1 was 
examined in the presence of biotin and pantothenic acid, a well-
known substrate for SMVT, and in the presence of folic acid and 
ascorbic acid for comparison (Fig. 3). Biotin and pantothenic acid 
induced significant inhibitory effects on the uptake of 5 in a 
concentration dependent manner whereas ascorbic acid and folic 
acid display no such effect. Similarly, a series of parallel experiments 
were also performed for the uptake of probe 2, the 
 
 
Fig. 3 (a) Effect on the uptake of 5 in in HeLa cells in the presence of vitamins biotin, 
pantothenic acid, ascorbic acid and folic acid. The cells were incubated with 2 μM of the 
probe in presence of the vitamin under high glucose serum free DMEM media at 37 ℃, 
λex = 458 nm, bandpath filter (505-550 nm). (b) Fluorescence intensity (F.I.) per cell in the 
images of the panel (a). The images were analysed by Image J software. The data are 
presented as mean ± SD (n =5). 
results clearly indicate that all vitamins used in this study fail to 
induce any inhibitory effect on the uptake of probe 2 (Fig. S4). These 
results indicate that 5 enters the cells selectively via SMVT, whereas 
the transport of 2 is independent of SMVT, confirming the 
differential uptake processes.  
Next, to demonstrate sodium ion-dependency for the uptake of 5, 
its cellular uptake behavior was examined in the presence of sodium 
ions and selective inhibitors for the sodium pump. As shown in Figure 
S5, depletion of sodium ions by replacing the salts with potassium 
salts in the media induced a drastic decrease in the uptake of 5. This 
result indicates that the sodium gradient across the plasma 
membrane is the driving force of the biotin-conjugate’s uptake, 
which is further confirmed by the inhibition of uptake by amiloride, 
a sodium ion transport inhibitor15 (Fig. S5 a, b). The replacement of 
chloride to phosphate in the media did not show any significant 
change in the uptake of probe 5. A gradual increase in 5’s cellular 
uptake is observed according to the increase of sodium ions in the 
range 0-100 mM (Fig. S5c). Similar experiments for the 
corresponding non-biotin probe 2 did not show any significant 
change (Fig. S5a, b, and S6). 
 
 
Fig. 4 Effect of various signal transduction pathway modulators on the uptake of 5 in 
HeLa cells such as genistein, forskolin, PMA and KN-62. (a) After preincubation of the 
cells with inhibitors for 1 hr. the cells were further incubated with 2 μM of a probe for 
10 min. under high glucose serum free DMEM media at 37 ℃. λex = 458 nm, bandpath 
filter (505-550 nm). (b) Fluorescence intensity (F.I.) per cell in the images of the panel 
(a). The images were obtained using Image J software. The data are presented as mean 
± SD (n =5). 
Considering that the sodium-dependent nutrient uptake as 
shown in this study is a typical characteristic of the secondary pump, 
biotin-conjugate uptake will depend on the cellular ATP level, which 
is examined in Fig. S7. Indeed, the uptake is clearly inhibited by the 
presence of ouabain,16 sodium azide17 or 2,4-dinitrophenol,18 which 
are an Na+/K+-ATPase inhibitor, an oxidative phosphorylation 
inhibitor and a mitochondrial uncoupler, respectively where all the 
chemicals reduce the cellular ATP level. Taken together with the 
results from Fig. 3 and Fig. S5, the results in Fig. S7 indicate that the 
cellular uptake of the biotin-conjugate in this study is via SMVT, a 
secondary pump whose driving force is regulated by the intracellular 
ATP hydrolysis. 
To check whether or not the physiological regulation of the SMVT 
activity for biotin uptake into cells works for the biotin-conjugates, 
the uptake of 5 into cells was investigated in the presence of the 
modulators for various signaling pathways; genistein,19 forskolin,20 
PMA21 and KN-6222 are used to modulate the protein tyrosine kinase 
(PTK), protein kinase A (PKA) as well as C (PKC) and calcium-
calmodulin pathways, respectively. As shown in Fig. 4, the 
fluorescence intensity from 5 is strongly inhibited by PMA, whereas 
the others did not show any effect, indicating that the biotin-
conjugates uptake is selectively controlled by protein kinase C 
activity. These results also demonstrate that the biotin-conjugates 
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are excellent candidates for cancer targeting imaging and drug 
delivery. Conversely, the uptake of the non-biotin system 2 was not 
changed in the presence of any of these modulators (Fig. S8). 
Aditionally, the viability of the cells was not affected by the presence 
of the biotin conjugates (Fig. S9). 
In summary, we have designed and developed biotinylated probes 
with varying hydrophilicity to investigate their cellular uptake 
mechanism and behavior. Compared with the non-biotinylated 
fluorescent probes, probe 5 exhibits preferential cellular uptake 
among other biotinylated probes through SMVT-protein receptors 
under sodium-ion dependent manner. In addition, the cellular 
uptake behavior is regulated under PKC-mediation by utilizing 
intracellular ATPs. Taken together, these data collectively highlight 
the critical role of hydrophilicity on the cellular uptake processes of 
biotin-based cancer targeting imaging agents. The use of these 
guidelines will expand the current cancer cell labelling/targeting 
toolbox and also offer the potential to improve their cellular uptake, 
which is crucial for the development of in vivo imaging systems and 
facilitate rational screening and allow for efficient diagnosis and 
monitoring of treatment response and more importantly patient 
satisfaction allowing for the implementation of precision medicine as 
part of standard patient care. 
This work was supported by CRI (No. 2009-0081566, JSK) and NRF 
(No. 2015R1A5A1037656, CK) of Korea. 
Notes and references 
1 (a) F. S. Collins, H. N. Varmus, Engl. J. Med. 2015, 372, 793; (b) 
S. Hawgood, I. G. Hook-Barnard, T. C. O’Brien, K. R. 
Yamamoto, Sci. Transl. Med. 2015, 7, 300ps17; (c) L. A. 
Chantrill, A. M. Nagrial, C. Watson, A. L. Johns, M. Martyn-
Smith, S. Simpson, S. Mead, M. D. Jones, J. S. Samra, A. J. Gill, 
N. Watson, V. T. Chin, J. L. Humphris, A. Chou, B. Brown, A. 
Morey, M. Pajic, S. M. Grimmond, D. K. Chang, D. Thomas, L. 
Sebastian, K. Sjoquist, S. Yip, N. Pavlakis, R. Asghari, S. Harvey, 
P. Grimison, J. Simes, A. V. Biankin, Clin. Cancer Res. 2015, 21, 
2029-2037. 
2 (a) A. Monica, V. Cecile, L. Sherene, L. Celine, M. Stefan, B. 
Herve, A. Fabrice, Nat. Rev. Clin. Oncol. 2015, 12, 693-704; (b) 
A. L. Richer, J. M. Friel, V. M. Carson, L. J. Inge, T. G. Whitsett, 
Pharmgenomics Pers. Med. 2015, 8, 63-79. 
3 (a) Y.-W. Jun, Y.-M. Huh, J.-S. Choi, J.-H. Lee, H.-T. Song, S. Kim, 
S. Yoon, K.-S. Kim, J.-S. Shin, J.-S. Suh, J. Cheon, J. Am. Chem. 
Soc. 2005, 127, 5732-5733; (b) N. Kosaka, H. Iguchi, T. Ochiya, 
Cancer Sci. 2010, 101, 2087-2092; (c) S. Ramaswamy, P. 
Tamayo, R. Rifkin, S. Mukherjee, C.-H. Yeang, M. Angelo, C. 
Ladd, M. Reich, E. Latulippe, J. P. Mesirov, T. Poggio, W. 
Gerald, M. Loda, E. S. Lander, T. R. Golub, Proc. Natl. Acad. Sci. 
U.S.A. 2001, 98, 15149-15154. 
4 (a) C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Adv. 
Drug Deliv. Rev. 1997, 23, 3-25; (b) R. C. Bast, T. L. Klug, E. S. 
John, E. Jenison, J. M. Niloff, H. Lazarus, R. S. Berkowitz, T. 
Leavitt, C. T. Griffiths, L. Parker, V. R. Zurawski, R. C. Knapp, N. 
Engl. J. Med. 1983, 309, 883-887; (c) W. C. S. Cho, T. T. C. Yip, 
C. Yip, V. Yip, V. Thulasiraman, R. K. C. Ngan, T.-T. Yip, W.-H. 
Lau, J. S. K. Au, S. C. K. Law, W.-W. Cheng, V. W. S. Ma, C. K. P. 
Lim, Clin. Cancer Res. 2004, 10, 43-52. 
5 (a) W. Yang, Y. Cheng, T. Xu, X. Wang, L. Wen, Eur. J. Med. 
Chem. 2009, 44, 862-868; (b) J. Zempleni, S. S. Wijeratne, Y. I. 
Hassan, BioFactors 2009, 35, 36-46. 
6 H. M. Said, J Nutr. 1999, 129, 490S-493S. 
7 (a) V. Kansara, S. Luo, B. Balasubrahmanyam, D. Pal, A. K. 
Mitra, Int. J. Pharm. 2006, 312, 43-52; (b) H. M. Said, Subcell. 
Biochem. 2012, 56, 1. 
8 (a) S. W. Park, D. E. Casalena, D. J. Wilson, R. Dai, P. P. Nag, F. 
Liu, J. P. Boyce, J. A. Bittker, S. L. Schreiber, B. C. Finzel, D. 
Schnappinger, C. C. Aldrich, Chem. Biol. 2015, 22, 76-86; (b) R. 
Kumar, J. Han, H.-J. Lim, W. X. Ren, J.-Y. Lim, J.-H. Kim, J. S. 
Kim, J. Am. Chem. Soc. 2014, 136, 17836-17843; (c) M. H. Lee, 
J. L. Sessler, J. S. Kim, Acc. Chem. Res. 2015, 48, 2935-2946; (d) 
R. Kumar, E.-J. Kim, J. Han, H. Lee, W. S. Shin, H. M. Kim, S. 
Bhuniya, J. S. Kim, K. S. Hong, Biomaterials 2016, 104, 119-
128; (e) W. S. Shin, J. Han, R. Kumar, G. G. Lee, J. L. Sessler, J.-
H. Kim, J. S. Kim, Sci. Rep. 2016, 6, 29018. 
9 (a) J. I. Stuckey, B. M. Dickson, N. Cheng, Y. Liu, J. L. Norris, S. 
H. Cholensky, W. Tempel, S. Qin, K. G. Huber, C. Sagum, K. 
Black, F. Li, X.-P. Huang, B. L. Roth, B. M. Baughman, G. 
Senisterra, S. G. Pattenden, M. Vedadi, P. J. Brown, M. T. 
Bedford, J. Min, C. H. Arrowsmith, L. I. James, S. V. Frye, Nat. 
Chem. Biol. 2016, 12, 180-187; (b) J. Su, F. Chen, V. L. Cryns, P. 
B. Messersmith, J. Am. Chem. Soc. 2011, 133, 11850-11853. 
10 (a) J. Wang, S. Rao, J. Chu, X. Shen, D. N. Levasseur, T. W. 
Theunissen, S. H. Orkin, Nature 2006, 444, 364-368; (b) H. Zhu, 
M. Bilgin, R. Bangham, D. Hall, A. Casamayor, P. Bertone, N. 
Lan, R. Jansen, S. Bidlingmaier, T. Houfek, T. Mitchell, P. Miller, 
R. A. Dean, M. Gerstein, M. Snyder, Science 2001, 293, 2101-
2105. 
11 (a) S. R. Sirsi, C. Fung, S. Garg, M. Y. Tianning, P. A. Mountford, 
M. A. Borden, Theranostics 2013, 3, 409-419; (b) X. Liu, B. 
Testa, A. Fahr, Pharm. Res. 2011, 28, 962-977. 
12 J. B. Rothbard, S. Garlington, Q. Lin, T. Kirschberg, E. Kreider, 
P. L. McGrane, P. A. Wender, P. A. Khavari, Nat. Med. 2000, 6, 
1253-1257. 
13 J.-P. Gratton, J. Yu, J. W. Griffith, R. W. Babbitt, R. S. Scotland, 
R. Hickey, F. J. Giordano, W. C. Sessa, Nat. Med. 2003, 9, 357-
362. 
14 P. Kucheryavy, G. Li, S. Vyas, C. Hadad, K. D. Glusac, J. Phys. 
Chem. A 2009, 113, 6453-6461. 
15 J. L. Kinsella, P. S. Aronson, Am. J. Physiol. 1981, 241, F374-F379. 
16 F. Proverbio, J. W. L. Robinson, G. Whittembury, Biochim. 
Biophys. Acta. Biomembr. 1970,  211, 327-336 
17 D. E. Keilin, E. F. Hartree, Proc. R. Soc. London Ser. B 1939,  127, 
167-191. 
18 (a) W. F. Loomis, F. Lipmann, J. Biol. Chem. 1948, 173, 807- 
808; (b) V. P. Skulachev, Biochim. Biophys. Acta 1998, 1363, 
100−124. 
19 T. Akiyama, J. Ishida, S. Nakagawa, H. Ogawara, S. Watanabe, 
N. Itoh, M. Shibuya, Y. Fukami, J. Biol. Chem. 1987, 262, 5592-
5595. 
20 K. B. Seamon, J. W. Daly, J. Cyclic Nucleotide Res. 1981, 7, 201-
224. 
21 T. J. Rink, A. Sanchez, T. J. Hallam, Nature 1983, 305, 317-319 
22 H. Tokumitsu, T. Chijiwa, M. Hagiwara, A. Mizutani, M. 
Terasawa, H. Hidaka, J. Biol. Chem. 1990, 265, 4315-4320. 
